Close Menu
    Facebook X (Twitter) Instagram
    BusinessNews.phBusinessNews.ph
    Subscribe
    • Top Stories
    • Business
    • Events / Conventions
    • National
    • Technology
    BusinessNews.phBusinessNews.ph
    Home » Impact BioMedical to Begin Efficacy Testing of Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc.
    Medical

    Impact BioMedical to Begin Efficacy Testing of Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc.

    By Marie JonesOctober 2, 2020Updated:October 4, 2020
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, today announced its wholly owned subsidiary Impact BioMedical, Inc. (“Impact BioMedical”) has formed a new wholly owned subsidiary, Innate Immune, Inc. (“Innate Immune”), to initiate efficacy testing of a pancoronavirus vaccine, a special type of vaccine designed to protect against multiple coronaviruses.

    “Highly pathogenic human coronaviruses are continuously emerging and remain a major threat to human health,” stated Daryl Thompson, Impact BioLife’s Director of Scientific Initiatives and founder of advanced research company GRDG Sciences, LLC (“GRDG”). Impact BioLife is a wholly owned subsidiary of Impact BioMedical. “Our pan-coronavirus vaccine is designed to allow us to not only protect against COVID-19, which is likely here to stay, but also allow for us to quickly respond to any outbreaks of a virus of this type in the future.”

    Coronaviruses are a large family of viruses and are common throughout the world. There are currently seven known human coronaviruses that can make people sick. Common human coronaviruses, including types 229E, NL63, OC43, and HKU1, usually cause mild to moderate upper-respiratory tract illnesses, while MERS-CoV, SARS-CoV, and now SARS-CoV2 can cause more severe pulmonary diseases.

    “COVID-19 has already cost more than one million lives and continues to disrupt the $133 trillion global economy,” commented Jason Grady, COO of DSS. “A successful pan-coronavirus vaccine could save countless lives while lessening or even preventing the types of disruptions we have seen this year that have impacted nearly everyone on the planet.”

    Innate Immune’s orally delivered pan-coronavirus vaccine has a well demonstrated safety profile and is designed to quickly be scaled for global distribution, ease of manufacturing, and high degree of stability. Innate Immune has gathered a globally recognized team of virologists to complete the research necessary to bring this vaccine to market.

    “The need for a solution to COVID-19 and potential future human coronaviruses is clear. We believe this vaccine can provide that solution while remaining economically affordable, ensuring availability across the globe” stated Chan Heng Fai, Chairman of DSS.

    GRDG’s Chief Scientific Advisor Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC commented, “This pan-coronavirus vaccine is designed to boost a human’s innate ability to fight viruses such as SARS-CoV2 by activating all phases of the human immune system. If successful, it could allow us to prevent further deaths and global economic disruptions from coronaviruses.”

    GRDG is a specialized research team that focuses on developing solutions for biodefense under the guidelines of the Project BioShield Act, Event 201, and Potomac Institute for Policy Studies.

    GRDG performs rapid analysis and research by using advanced algorithms and the most complete databases in the world. The team operates in a lean and efficient manner and when necessary utilizes the top contract research organizations to deliver solid results that are robust and accurate.

    About Impact BioMedical, Inc.
    Impact BioMedical, Inc. (“Impact BioMedical”) is a wholly owned subsidiary of DSS. Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases. For more information on Impact BioMedical visit http://impbio.com/.

    About Document Security Systems, Inc.
    DSS is a multinational company operating businesses focused on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. Its historic business revolves around counterfeit deterrent and authentication technologies, smart packaging, and consumer product engagement. DSS is led by its Chairman and largest shareholder, Mr. Fai Chan, a highly successful global business veteran of more than 40 years specializing in corporate transformation while managing risk. He has successfully restructured more than 35 corporations with a combined value of $25 billion. For more information on DSS visit http://www.dsssecure.com.

    Investor Contact:
    Dave Gentry, CEO
    RedChip Companies Inc.
    407-491-4498
    Dave@redchip.com

    For the latest business and finance news in Asia - Business News Asia
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability

    July 18, 2025

    Belgian Aircrew Completes MQ-9B Training

    July 18, 2025

    Cornerstone Robotics Signs MOU with NHG Health and NTU Singapore to Facilitate Accessibility of RAS to Patients in Singapore

    July 17, 2025
    Latest News

    Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability

    July 18, 2025

    Belgian Aircrew Completes MQ-9B Training

    July 18, 2025

    A New Transatlantic Partnership for European CCA

    July 18, 2025

    IP Roundtable and International Publishing Forum held at Hong Kong Book Fair today

    July 18, 2025

    Cornerstone Robotics Signs MOU with NHG Health and NTU Singapore to Facilitate Accessibility of RAS to Patients in Singapore

    July 17, 2025

    BlackBerry Partners with EC-Council to Help Strengthen Malaysia’s Cybersecurity Workforce

    July 17, 2025

    “TOKIO Exciting Anime Workshop” Confirmed – Enjoy “Summer Festival at Anime Tokyo Station” This Summer Vacation

    July 17, 2025

    Global Sports Brand U.S. Polo Assn. Launches First Retail Store in Berlin, Germany

    July 17, 2025

    Hong Kong Book Fair, Sports and Leisure Expo and World of Snacks open today

    July 17, 2025

    International Land Alliance Unveils New Revenue Model Featuring 100 Rental Homes in Cabo Oasis

    July 16, 2025

    Doubleview Gold Corp Provides Comprehensive Update on Its Flagship Project – the Polymetallic Hat Deposit

    July 16, 2025

    Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition – New Designs Added for Admission Bonus Illustration Cards

    July 16, 2025

    Formerra to Supply Foster Medical Compounds Across the Americas

    July 15, 2025

    U.S. Polo Assn. Celebrates Seventh Year Supporting the 2025 Outsourcing Inc. Royal Charity Polo Cup

    July 15, 2025

    AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease

    July 15, 2025
    BusinessNews.ph
    • Home
    • Business News Asia
    • Cebu Lifestyle Channel
    • Property News
    • Events News Asia.com
    • Contact Us
    • Cebu Business News
    © 2025 All Rights Reserved | BusinessNews.ph

    Type above and press Enter to search. Press Esc to cancel.